BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 22568935)

  • 1. Implementing community-based provider participation in research: an empirical study.
    Teal R; Bergmire DM; Johnston M; Weiner BJ
    Implement Sci; 2012 May; 7():41. PubMed ID: 22568935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustainability and performance of the National Cancer Institute's Community Clinical Oncology Program.
    Carpenter WR; Fortune-Greeley AK; Zullig LL; Lee SY; Weiner BJ
    Contemp Clin Trials; 2012 Jan; 33(1):46-54. PubMed ID: 21986391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Why providers participate in clinical trials: considering the National Cancer Institute's Community Clinical Oncology Program.
    McAlearney AS; Song PH; Reiter KL
    Contemp Clin Trials; 2012 Nov; 33(6):1143-9. PubMed ID: 22925970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Organizational and physician factors associated with patient enrollment in cancer clinical trials.
    Jacobs SR; Weiner BJ; Reeve BB; Weinberger M; Minasian LM; Good MJ
    Clin Trials; 2014 Oct; 11(5):565-75. PubMed ID: 24902923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determining the predictors of innovation implementation in healthcare: a quantitative analysis of implementation effectiveness.
    Jacobs SR; Weiner BJ; Reeve BB; Hofmann DA; Christian M; Weinberger M
    BMC Health Serv Res; 2015 Jan; 15():6. PubMed ID: 25608564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance in quasi-firms: an example from the Community Clinical Oncology Program.
    Lacey LM; Hynes DM; Kaluzny AD
    J Health Hum Resour Adm; 1992; 14(3):307-26. PubMed ID: 10118501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting the performance of a strategic alliance: an analysis of the Community Clinical Oncology Program.
    Kaluzny AD; Lacey LM; Warnecke R; Hynes DM; Morrissey J; Ford L; Sondik E
    Health Serv Res; 1993 Jun; 28(2):159-82. PubMed ID: 8514498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating organizational design to assure technology transfer: the case of the Community Clinical Oncology Program.
    Kaluzny AD; Ricketts T; Warnecke R; Ford L; Morrissey J; Gillings D; Sondik EJ; Ozer H; Goldman J
    J Natl Cancer Inst; 1989 Nov; 81(22):1717-25. PubMed ID: 2681795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Organizational designs for achieving high treatment trial enrollment: a fuzzy-set analysis of the community clinical oncology program.
    Weiner BJ; Jacobs SR; Minasian LM; Good MJ
    J Oncol Pract; 2012 Sep; 8(5):287-91. PubMed ID: 23277765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A method for analyzing the business case for provider participation in the National Cancer Institute's Community Clinical Oncology Program and similar federally funded, provider-based research networks.
    Reiter KL; Song PH; Minasian L; Good M; Weiner BJ; McAlearney AS
    Cancer; 2012 Sep; 118(17):4253-61. PubMed ID: 22213241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges and facilitators of community clinical oncology program participation: a qualitative study.
    McAlearney AS; Reiter KL; Weiner BJ; Minasian L; Song PH
    J Healthc Manag; 2013; 58(1):29-44; discussion 45-6. PubMed ID: 23424817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating productivity in clinical research programs: the National Cancer Institute's (NCI) Community Clinical Oncology Program (CCOP).
    Hynes DM; McLaughlin CP; Kaluzny AD; Ford LP; Sondik E
    J Med Syst; 1992 Dec; 16(6):247-67. PubMed ID: 1304594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ecological analysis of the first generation of community clinical oncology programs.
    Schopler JH
    Health Serv Res; 1993 Apr; 28(1):69-95. PubMed ID: 8463110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accrual to National Cancer Institute-sponsored non-small-cell lung cancer trials: insights and contributions from the CCOP program.
    Lyss AP; Lilenbaum RC
    Clin Lung Cancer; 2009 Nov; 10(6):410-3. PubMed ID: 19900858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reforming the community research program: from Community Clinical Oncology Program to the National Cancer Institute Community Oncology Research Program.
    Zon RT
    Am Soc Clin Oncol Educ Book; 2014; ():e116-9. PubMed ID: 24857089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Community Clinical Oncology Program (CCOP) story: review of community oncologists' experiences with clinical research trials in cancer with an emphasis on the CCOP of the National Cancer Institute between 1982 and 1987.
    Frelick RW
    J Clin Oncol; 1994 Aug; 12(8):1718-23. PubMed ID: 8040683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Provider-based research networks and diffusion of surgical technologies among patients with early-stage kidney cancer.
    Tan HJ; Meyer AM; Kuo TM; Smith AB; Wheeler SB; Carpenter WR; Nielsen ME
    Cancer; 2015 Mar; 121(6):836-43. PubMed ID: 25410684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enrollment of adolescents and young adults onto SWOG cancer research network clinical trials: A comparative analysis by treatment site and era.
    Roth ME; Unger JM; O'Mara AM; Lewis MA; Budd T; Johnson RH; Pollock BH; Blanke C; Freyer DR
    Cancer Med; 2020 Mar; 9(6):2146-2152. PubMed ID: 32009305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Achieving high cancer control trial enrollment in the community setting: an analysis of the Community Clinical Oncology Program.
    Jacobs SR; Weiner BJ; Minasian LM; Good MJ
    Contemp Clin Trials; 2013 Mar; 34(2):320-5. PubMed ID: 23295315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of managed care and competition on community-based clinical research.
    Carpenter WR; Weiner BJ; Kaluzny AD; Domino ME; Lee SY
    Med Care; 2006 Jul; 44(7):671-9. PubMed ID: 16799362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.